TARS Tarsus Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-09 16:00
Why TARS matters now
Tarsus Pharmaceuticals, Inc. (TARS) is a US stock in Healthcare. The latest InvestLog snapshot shows $64.14 with -5.30% on the session and $2.76B in market capitalization; recent performance reads 1-month +3.05% and YTD -22.86%.
The latest financial table shown here is Q1 2026, with revenue of $162.1M, net income of $-7.0M, and EPS of $-0.16. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.2%.
The latest indexable market news headline is "Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug" from Benzinga.
Additional event context on this page matters because analyst consensus is Buy with a median target of $68.00; recent insider activity includes Farrow Jeffrey S filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.78
P/S
5.08
EV/EBITDA
-67.29
DCF Value
$-450.07
FCF Yield
-1.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.4%
Operating Margin
-9.5%
Net Margin
-9.0%
ROE
-14.2%
ROA
-8.3%
ROIC
-11.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $162.1M | $-7.0M | $-0.16 |
| Q4 2025 | $151.7M | $-8.4M | $-0.20 |
| FY 2025 | $451.4M | $-66.4M | $-1.59 |
| Q3 2025 | $118.7M | $-12.6M | $-0.30 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$68.00
Target (Median)
$68.00
Target Range
$68.00 - $68.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.51
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.